President Joe Biden recently gave an update on his treatment for metastatic prostate cancer. A urologist explains ways to ...

Women with de novo metastatic breast cancer that is confined to a single distant organ may live longer when they undergo resection of the primary tumor, a large cohort study suggested. The study, of ...

Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, with ...

HER2-directed therapies, including monoclonal antibodies, ADCs, and TKIs, have improved survival in HER2-positive breast cancer patients. Clinical trials like CLEOPATRA, DESTINY-Breast01, and ...

At the ASCO annual meeting, Dana-Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously ...

A shift in the way people think about and treat pancreatic cancer could be on the horizon based on positive results from the pivotal randomized Phase III RASolute 302 trial comparing daraxonrasib to ...

This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract does not include a full text component.

Please provide your email address to receive an email when new articles are posted on . Daraxonrasib nearly doubled survival vs. chemotherapy for pretreated patients with metastatic pancreatic cancer.